Real‐world effectiveness and safety of switching to dolutegravir/lamivudine among people living with <scp>HIV</scp>‐1 aged over 50 years who are virologically suppressed
DTG/3TC demonstrated robust effectiveness and a good safety profile in individuals aged >50 years with virological suppression in Portugal.
Authors
- Lurdes Santos (ORCID: https://orcid.org/0000-0002-0622-6823)
- Rosário Serrão (ORCID: https://orcid.org/0000-0002-3030-1205)
- Carmela Piñeiro
- Sara Policarpo (ORCID: https://orcid.org/0000-0001-8594-1720)
- V. Paul DiMondi
- Carlos Caldas (ORCID: https://orcid.org/0000-0003-3547-1489)
- I. de Augusto
Institutions
- Hospital de São João (PT)
Publication Details
- Journal
- HIV Medicine
- Published
- 2024-09-06
- DOI
- https://doi.org/10.1111/hiv.13699
- Citations
- 1
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.39
Funders
- Gilead Sciences
- ViiV Healthcare